Ratings Frontage Holdings Corporation

Equities

1521

KYG3679P1019

Market Closed - Hong Kong S.E. Other stock markets 04:09:09 2024-04-25 am EDT			5-day change	1st Jan Change
1.3 ^HKD	+4.00%		-4.41%	-43.97%

Apr. 01	Frontage Holdings' Net Profit Plunges 59% in 2023	MT
Mar. 28	Frontage Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Strengths

The company's share price in relation to its net book value makes it look relatively cheap.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last few months, analysts have been revising downwards their earnings forecast.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
FRONTAGE HOLDINGS CORPORATION	-43.97%	323M	-
IQVIA HOLDINGS INC.	+1.61%	43.84B	B
MODERNA, INC.	+6.04%	41.68B	B-
LONZA GROUP AG	+45.04%	41.25B	A
CELLTRION, INC.	-10.92%	27.04B	C
ICON PUBLIC LIMITED COMPANY	+7.41%	25.53B	B-
ALNYLAM PHARMACEUTICALS, INC.	-25.43%	18.18B	B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.28%	12.29B	C+
MEDPACE HOLDINGS, INC.	+26.58%	12.29B	C+
UNITED THERAPEUTICS CORPORATION	+6.79%	11.15B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes